Abstract Cisplatin or (SP-4-2)-diamminedichloridoplatinum (II) is one of the most potential
and widely used drugs for the treatment of various solid cancers such as testicular, ovarian …

Cisplatin is a widely used chemotherapy agent in the treatment of various forms of
carcinomas and sarcomas. Its effectiveness in delaying negative outcome in cancer patients …

Background High-risk triple-negative breast cancers (TNBCs) are characterized by poor
prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy …

Cisplatin, cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known
chemotherapeutic drug. It has been used for treatment of numerous human cancers …

Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 …

In the realm of drug delivery, carbon nanotubes (CNTs) have gained tremendous attention
as promising nanocarriers, owing to their distinct characteristics, such as high surface area …

Cisplatin, carboplatin and oxaliplatin are platinum-based drugs that are widely used in
cancer chemotherapy. Platinum–DNA adducts, which are formed following uptake of the …

Purpose Epidermal growth factor receptor (EGFR) is a targetable receptor frequently
overexpressed in basal-like breast cancer, which comprises most triple-negative breast …

Cancer metastasis is responsible for the vast majority of cancer‐related deaths worldwide. In
contrast to numerous discoveries that reveal the detailed mechanisms leading to the …

Cisplatin has dramatically improved the survival rate of cancer patients, but it has also
increased the prevalence of hearing and neurological deficits in this population. Cisplatin …